

Corporate governance

CellaVision is a Swedish public limited liability company with its registered office in Lund. Apart from the parent company, the Group consists of five wholly-owned subsidiaries in Sweden, the USA, Canada, Japan and France, as well as offices for local market support in the USA, Canada, Brazil, China, Japan, South Korea, Australia, Sweden, United Arab Emirates, France, Germany, the United Kingdom, Mexico, India, Thailand, Spain and Italy. The company's share is listed on NASDAQ Stockholm. CellaVision applies the Swedish Code of Corporate Governance (the Code) since its shares were admitted to trading in 2010 and reports no deviations from the Code for 2019.

The term corporate governance normally refers to the rules and structure built up to govern and direct a limited liability company in an effective and controlled manner. Governance and control of CellaVision is divided between the shareholders at the Annual General Meeting, the Board of Directors and the President/CEO, and is regulated in legislation (including the Companies Act), the Articles of Association, the Nasdaq Stockholm rule book for issuers and the Swedish Code of Corporate Governance. The code is available at www.bolagsstyrrning.se.

In addition to legal control and governance principles, CellaVision is also influenced by several internal policy documents, including instructions and rules of procedure for the President/CEO and Board of Directors, as well as internal policies and guidelines.

Shareholders

The share capital on December 31, 2019 was SEK 3,577,732, distributed among 23,851,547 shares. Each share entitles the holder to one vote and each person entitled to vote at a general meeting of shareholders may vote for the full number of shares owned and represented by her or him without limit to the voting right. All shares confer an equal right to share in the company's assets and profits. CellaVision

had 9,286 (7,412) shareholders on the closing date. Of these, two shareholders have direct and indirect holdings constituting more than ten percent of the votes and capital: William Demant Invest A/S and State Street Bank. No shares are held by the company itself. For further information about the CellaVision share and shareholders please refer to pages 27–28 and CellaVision's website.

Articles of Association


The Articles of Association of CellaVision stipulate that the company shall develop, market and sell products in sample preparation and systems for automated digital microscopy, specializing in software applications for the medical market. The registered office of the company is in Lund and the company's financial year is a calendar year. In other respects, the Articles of Association contains provisions concerning the number of shares, number of board members and auditor and the Annual General Meeting. The Articles of Association contain no separate provisions concerning the appointment or removal of Members of the Board or

concerning amendments to the Articles of Association. The complete Articles of Association can be downloaded from www.cellavision.se.

General Meeting of Shareholders

Shareholders exercise their influence over CellaVision at the General Meeting of Shareholders, which is the highest decision-making body in CellaVision. The General Meeting is called at least once a year and among other things passes resolutions on the treatment of the company's and Group's balance sheet and income statement including the appropriation of the company's profits, discharge from liability of the Board of Directors and President/CEO, election of the Board of Directors and auditor, fees to the Board of Directors and auditor and appointment of the Nomination Committee. Amendments to the Articles of Association require a resolution by the General Meeting of Shareholders. To participate in the General Meeting the shareholder must be entered under his or her own name in the register of shareholders at least five business days before the Meeting and notify the intention

Overall governance structure for CellaVision



to attend to the company at the latest on the date specified in the notice to attend. At the General Meeting the shareholder must attend either in person or via a representative. The Annual General Meeting is held in Lund during the first half of every year. In connection with the third quarterly report CellaVision's shareholders are informed of the time and place of the Annual General Meeting and of their right to bring a matter before the Meeting. A notice to attend the Annual General Meeting is published no earlier than six and no later than four weeks before the Meeting. An extraordinary general meeting may be held if the Board of Directors considers it necessary or if the company's auditors or shareholders holding at least ten percent of the shares so requests.

Annual General Meeting 2019

CellaVision's Annual General Meeting was held on Wednesday, May 8, 2019 at CellaVision's address, Mobilvägen 12 in Lund. The Meeting was attended by 44 (39) shareholders, in person or through representatives. They represented about 55 (48) percent of the total votes. The Board of Directors, Nomination Committee and auditor of the company were present at the Meeting. Essentially, the following resolutions were passed:

- The parent company and consolidated income statements and balance sheets were adopted. It was further resolved that a dividend of SEK 1.50 per share would be distributed for the 2018 financial year.
- Discharge from liability of the members of the Board of Directors and the President.
- Re-election of Christer Fåhræus, Åsa Hedin, Anna Malm Bernsten, Sören Mellstig, Niklas Prager, Jürgen Riedl and Stefan Wolf as Board Members. Sören Mellstig was re-elected as Chair of the Board. Re-election of Deloitte AB as auditor.
- Fee to the Board of Directors, presented in the table on page 46 and in Note 15 of the annual report.
- Guidelines for remuneration to senior management. A resolution was also passed concerning an incentive program for the company management.
- Principles for the Nomination Committee.
- A dividend policy was adopted.

The minutes of the Annual General Meeting were presented on the website within a week of the Meeting. Material from the Meeting, such as the notice to attend, the minutes and information on the Nomination Committee is available on CellaVision's website. The full resolutions of the Meeting as above are available from the Company at the address Mobilvägen 12 in Lund and will be sent to any shareholder who so requests.

Nomination Committee

The main task of the Nomination Committee is to propose to the Annual General Meeting the composition of the Board of Directors, which is then decided by the Annual General Meeting. The work of the Nomination Committee starts by studying the evaluation of the work of the Board of Directors commissioned by the Board of Directors. The work of the Nomination Committee is characterized by transparency and discussion to achieve a well-balanced Board. The Nomination Committee then nominates members to the Board for the next term of office and submits proposals for remuneration to the Board of Directors and auditors and, where applicable, also for election of auditor.

Nominating Committee for the Annual General Meeting in 2020

In accordance with a resolution of the 2019 Annual General Meeting, CellaVision's Nomination Committee ahead of the 2020 Annual General Meeting shall consist of one representative of each of the four largest shareholders in terms of voting rights at the end of August 2019. The Chair of the Board convenes the first meeting of the Nomination Committee and is co-opted to the meetings of the Nomination Committee. The composition of the Nomination Committee was announced on October 23 in connection with the interim report for January-September 2019. The members of the Nomination Committee and the shareholders who appointed them is presented in the table below. The chair of the Nomination Committee ahead of the 2020 Annual General Meeting was Christer Fåhræus.

In 2019 the Nomination Committee held three meetings as well as a number of email and telephone contacts. The Nomination Committee proposals are presented, in

addition to the press release, in the notice to attend the 2020 Annual General Meeting and are also available on the company's website together with an explanatory statement concerning the proposed Board of Directors.

Name/Representing	Voting share (31/12 2019)
Sören Mellstig, in cap of Board Chair co-opted.	
Nicklas Hansen, William Demant Invest A/S	13.6 %
Christer Fåhræus, Christer Fåhræus and comp.	9.7 %
Joel Eklund, Grenlunden CEVI AB	9.6 %
Bo Lundgren, Swedbank Robur Fonder	7.4 %
Total	40.3 %

Board of Directors

The Board of Directors and ultimately the President/CEO administers the affairs of the company on behalf of the shareholders. The Board of Directors appoints the President/CEO, who is responsible for the day-to-day management of the company. The division of duties and responsibilities between the Board of Directors and the President/CEO is clarified in the Board's Rules of Procedure and the Instructions to the President/CEO.

The Board of Directors is appointed by the shareholders at the Annual General Meeting with a term of office up to and including the next Annual General Meeting. The Board of Directors manages the company on behalf of the owners by establishing goals and strategy, evaluating the operative management and ensuring that there is an effective system for follow-up and control of the established goals. It is also the responsibility of the Board to ensure that the company's information provision is correct, relevant and reliable.

The Board of Directors forms a quorum when more than half of its members are present. Under CellaVision's Articles of Association the Board of Directors must consist of a minimum of three and a maximum of nine members with a maximum of two alternates. The Board holds an inaugural meeting directly after the Annual General Meeting.

Chair of the Board

CellaVision's Board of Directors has been chaired since 2016 by Sören Mellstig. The Chair of the Board is appoint-

ed by the Annual General Meeting. The Chair of the Board organizes and leads the work of the Board, ensures that the Board regularly develops its knowledge of the company, communicates shareholders' views to the Board and is a support to the President/CEO. The Chair of the Board and the President/CEO prepare proposed agendas for the Board meetings. It is the responsibility of the Chair of the Board to verify that the Board's decisions are effectively implemented and that the work of the Board is evaluated annually and that the Nomination Committee is informed of the results of this evaluation.

The Board's Rules of Procedure

The Board of Directors adopts rules of procedure for its work annually. The current rules of procedure were adopted on May 8, 2019. In addition to that, the Rules of Procedure are revised as necessary. The Rules of Procedure include a description of the responsibilities and duties of the Board, the duties of the Chair of the Board, audit issues and specify the reports and financial information that the Board must receive before each ordinary Board meeting.

Evaluation of the work of the Board

Under the leadership of the Chair, the Board conducts an annual evaluation of its work. The evaluation refers to forms

of work and work climate, emphasis of the Board's work and access to and need for special competence in the Board. The evaluation is used as an aid for developing the work of the Board. In accordance with the Swedish Code of Corporate Governance, relevant parts of the results are made available to the Nomination Committee.

Composition of the Board of Directors in 2019

In 2019 the Board of Directors consisted of seven members with no alternates. At the 2019 Annual General Meeting Christer Fåhræus, Åsa Hedin, Anna Malm Bernsten, Sören Mellstig, Niklas Prager, Jürgen Riedl and Stefan Wolf were re-elected as Board Members. Sören Mellstig was re-elected as Chair of the Board. The members of the Board have great experience and competence in medicine and technology as well as business and international operations. The composition of the Board complies with the requirements of the Code regarding independent members. The information that is to be provided under point 10.2 of the Code concerning members of the Board can be found on page 50.

Work of the Board in 2019

In 2019 CellaVision's Board of Directors held a total of 11 minuted meetings, four of which by telephone. Four of the meetings were held in connection with the approval of the

year-end bulletin and the interim reports. On occasions when any member has been prevented from attending the Chair of the Board has obtained views concerning the decision in advance. Important questions during the year included the acquisition of RAL Diagnostics, strategy, market assessments and material risks.

The company's President/CEO and CFO participate regularly in the Board meetings. Other senior executives participate in the Board meetings as necessary. The company's auditor participated in the February Board meeting, when the year-end bulletin was approved.

Audit Committee

Risks concerning CellaVision's financial reporting are monitored and evaluated by the Board's Audit Committee, whose main task is to support the Board in quality assurance of the financial reporting. The Audit Committee has no decision-making authority, it prepares and reports matters to the Board as a whole.

The Audit Committee consists of three members who are all independent in relation to the company and its management as well as being independent in relation to the company's major shareholders: Sören Mellstig, Anna Malm Bernsten and Niklas Prager, where Niklas Prager chairs the Committee. During the year the Committee met twice. Questions dealt with are mainly internal control in the subsidiaries, risks, audit planning and governance and follow-up of operations. The company's auditor and CFO participate regularly at the Audit Committee meetings.

Remuneration Committee

The Board of Directors also has a Remuneration Committee, whose main task is to propose principles for remuneration and other conditions of employment for the President/CEO and other senior management in the Group. Ahead of each Annual General Meeting the Committee submits its proposals, in accordance with Chapter 8, Section 51 of the Swedish Companies Act.

Attendance and remuneration of the Board 2019

Name	Independence in to company	Independence to major shareholder	Audit Committee	Remuneration Committee	Board fees, SEK t	Attendance at Board meetings
Sören Mellstig	Yes	Yes	Member	Chairman	539	11/11
Christer Fåhræus	Yes	No		Member	226	9/11
Torbjörn Kronander*	Yes	Yes		Member	92	3/4
Anna Malm Bernsten	Yes	Yes	Member		235	9/11
Niklas Prager	Yes	Yes	Chairman		255	11/11
Åsa Hedin	Yes	Yes		Member	235	9/11
Jürgen Riedl	Yes	Yes			215	11/11
Stefan Wolf	Yes	Yes			215	6/11
Total					2 012	

* Torbjörn Kronander was a member of the Board until the Annual General Meeting on May 8, 2019.

A more detailed presentation of the Board members can be found on page 50 and on the company's website www.cellavision.se

In 2019 the Remuneration Committee consisted of members of the Board Sören Mellstig, Christer Fåhræus and Åsa Hedin, who are all independent of the company and the company management. Sören Mellstig chairs the Committee. During the year the Committee held one minuted meeting, and conducted several telephone and email contacts. In addition to guidelines and principles of remuneration to the President/CEO and other senior management during the year the Committee discussed the company's incentive program for the President/CEO, management and other staff.

President/CEO and Executive Group Management

The President/CEO is appointed by and receives instructions from the Board of Directors. CellaVision's President and Chief Executive Officer in 2019, Zlatko Rihter, was responsible for the day-to-day management of the company as well as strategic and operative issues, in accordance with the Board's guidelines and directions. The current Instruction to the President/CEO was adopted by the Board on May 8, 2019. The President/CEO prepares information and decision-making data for the Board meetings and is presenter at the meetings. The Board of Directors continuously evaluates the work of the President/CEO through monitoring against goals set. Once a year a formal evaluation is made, which is discussed with the President/CEO.

Composition of the management in 2019

The President/CEO has appointed a management team to be responsible for various parts of CellaVision's business. In 2019 the Executive Group Management consisted of nine people besides the President/CEO:

- Chief Financial Officer (CFO)
- VP Supply & Sourcing
- VP Quality
- VP Business Development
- VP Human Resources & Corporate Communications
- VP Global Sales
- VP Global Marketing
- VP Innovation & Engineering

December 2
Budget and business plan

October 22
Innovation
Interim report

September 5
The customer
Follow-up strategy meeting

August 9 (telco)
Follow-up acquisition

July 16 (telco)
Interim report

- The head of the subsidiary RAL Diagnostics (from the fourth quarter)

Apart from the head of the subsidiary RAL Diagnostics, all the members of the Executive Group Management are at the company's head office in Lund, Sweden. The Executive Group Management holds minuted meetings at which operative issues are discussed. The Executive Group Management draws up a business plan annually, which is adopted by the Board. A more detailed presentation of the President/CEO and the management team can be found on pages 51. The information on the President/CEO stipulated in item 10.2 of the Code can also be found there.

Auditor

The administration of the Board of Directors and the President/CEO and financial reporting is examined by the

Board meetings 2019



January 24 (telco)
Update acquisition

February 6
People
Year-end bulletin
Audit report

May 6 (telco)
Interim report

May 8
Board meeting
prior to AGM

May 8
Inaugural meeting

June 13
Strategy meeting

external auditor elected by the Annual General Meeting. The auditor is proposed by the Nomination Committee and elected by the Meeting for one year. At the 2019 Annual General Meeting Deloitte was re-elected as auditor up to and including the 2020 Annual General Meeting.

The auditor in charge is authorized public accountant Maria Ekelund. The task of the auditor is to audit CellaVision's annual accounts, accounting records and the administration by the Board of Directors and President/CEO on behalf of the shareholders. Besides the annual audit, the auditor reviews at least one interim report per year. Remuneration to the auditor is payable in accordance with the approved invoice. For amounts please see Note 16.

Remuneration

Salaries, remuneration and other benefits to the Board of Directors, President/CEO and other senior management are reported in Note 15 in the annual report. Remuneration to the Board of Directors can also be followed in the table on page 46.

Guidelines for remuneration to senior management in 2019

The Annual General Meeting 2019 resolved to approve the Board's proposal with guidelines for remuneration to senior executives in CellaVision AB as follows: "The company is to offer commercially based total remuneration that enables the recruitment and retention of senior management. The remuneration to company management is to consist of fixed salary, benefits in kind, variable remuneration and pension. Fixed salary plus variable salary together constitute the individual's target salary.

The fixed salary is to take account of the individual's areas of responsibility and experience and be reviewed annually. The distribution between the fixed salary and variable remuneration must be in proportion to the responsibility and authority of the person holding the position. The variable remuneration must always be subject to predetermined limits and be linked to predetermined and measurable performance criteria. The variable remuneration to the President/CEO must be based on individual targets established by the Board. These targets shall be linked to the company's overall targets including earnings, sales and/or cash flow. For other senior management variable remuneration is to be based on equivalent targets and targets within their own area of responsibility.

Pension conditions must be commercial in relation to market conditions applicable to others holding equivalent positions and must be based on defined contribution plan solutions. The retirement age is to be 65 years. Severance pay for a member of the management can be payable in an amount equivalent to a maximum of 12 months' salary. The total of the fixed salary during the period of notice and severance pay may not exceed an amount equivalent to two years' fixed salary for the member of management. No

separate board fee is payable to a member of management holding a position as member or alternate in a group company board of directors."

The Board of Directors may deviate from these guidelines if there are special grounds for this in an individual case.

Long-term incentive program for senior management

In line with the AGM's decision on remuneration on the 8th of May 2019, the Board decided on an incentive program for the company's senior management in 2019/2021. The outcome of the program is dependent on the company's earnings and sales growth as well as the annual average growth of the company's profit per share. The maximum remuneration is payable if the annual average growth of the company's profit per share in the period January 1, 2019 – December 31, 2021 is at least 15 percent annually. For maximum outcome the company's costs for the incentive program are estimated to be SEK 3.2 million (excluding social security contributions), based on participation of nine members of senior management in the incentive program. To share in the outcome from the incentive program the member of senior management must be employed by the company on December 31, 2021. The cost is accrued over three years, corresponding to the duration of the program and any payment will be made in 2022.

The resolution means that the company, provided profitability and sales targets set by the Board at the start of 2019 have been achieved, will set aside 3 monthly salaries for the CEO, 1 monthly salaries for the VP Global Sales and 1.5 monthly salaries for other senior management participating in the incentive program in 2019.

Moreover, the company has a program from 2018 that continues to run, which is presented in the annual report for 2018. The program will close on December 31, 2020 and any payment will be made in 2021. For maximum outcome the company's costs for the program are estimated to be SEK 2.9 million (excluding social security contributions), based on participation of eight members of senior management in the program.

The cost of the company's program from 2017, which is reported in the annual report for 2017, and which ends on December 31, 2019, amounted to SEK 2.6 million (excluding social security contributions). Payment was made in accordance with the terms of the program during the first quarter of 2020.

Staff incentive program

The Board approved an incentive program for staff in 2019 that ran from January 1, 2019 to December 31, 2019. Eligible staff were those who were not senior management or covered by other incentive programs and who consequently were not eligible for the incentive program for senior management resolved by the 2019 Annual General Meeting.

The decision meant that the employee will receive 0.5 of a monthly salary in the case of maximum outcome. The size of the share depended on the company's performance and sales in 2019. To participate in the incentive program the employee had to have been employed for at least six months in 2019 and be employed on December 31, 2019. The program for 2019 achieved the profitability and sales targets set up to 89,4% percent and therefore the cost to the company for the outcome of the bonus program to staff was SEK 2.7 million.

Proposed guidelines for remuneration to senior management in 2020

The Board of Directors proposes the following guidelines for remuneration to senior management in 2020, as in last year's proposal: "The company is to offer commercially based total remuneration that enables the recruitment and retention of senior management. The remuneration to company management is to consist of fixed salary, benefits in kind, variable remuneration and pension. Fixed salary plus variable salary together constitute the individual's target salary.

The fixed salary is to take account of the individual's areas of responsibility and experience and be reviewed annually. The distribution between the fixed salary and variable remuneration must be in proportion to the responsibility and

authority of the person holding the position. The variable remuneration must always be subject to predetermined limits and be linked to predetermined and measurable performance criteria. The variable remuneration to the President/CEO must be based on individual targets established by the Board. These targets shall be linked to the company's overall targets including earnings, sales and/or cash flow. For other senior management variable remuneration is to be based on equivalent targets and targets within their own area of responsibility.

Pension conditions must be commercial in relation to market conditions applicable to others holding equivalent positions and must be based on defined contribution plan solutions. The retirement age is to be 65 years.

Severance pay for a member of the management can be payable in an amount equivalent to a maximum of 12 months' salary. The total of the fixed salary during the period of notice and severance pay may not exceed an amount equivalent to two years' fixed salary for the member of management. No separate board fee is payable to a member of management holding a position as member or alternate in a group company board of directors.

The Board of Directors may deviate from these guidelines if there are special grounds for this in an individual case."

The Board's report on internal controls and risk management referring to financial reporting

This report on internal control referring to financial reporting is submitted by the Board of CellaVision and has been drawn up in accordance with the Swedish Code of Corporate Governance.

Background

Under the Companies Act and the Swedish Code of Corporate Governance the Board is responsible for internal control.

Control environment

The basis of internal control is the overall control environment. A good control environment builds on an organization with clear decision lines where responsibility and authority is clearly defined. In CellaVision there are policies, guidelines and process descriptions for the different parts of the business flow from transaction management to bookkeeping and preparing external reports.

In the company's financial and accounting manual, Administrative Guidelines, which is updated annually, these process descriptions are presented in all essentials.

Risk assessment

The Board and Audit Committee are responsible for identifying and managing all material financial risks and risks of misstatements in the external reporting. The Audit Committee evaluates the risk management requirements annually and draws up written principles both for overall risk management and for specific areas, such as currency risk, interest rate risk, credit risk and investment of surplus liquidity. These principles are then adopted by the Board.

Control activities

The main purpose of control activities is to prevent and discover errors as soon as possible in order to rectify any deficiencies. Procedures and activities have been designed to discover and deal with the most material risks related to financial reporting. Group companies are followed up by the CEO and CFO through regular reports and personal meetings with the management of the respective subsidiary. The Board receives monthly reports in which the CEO and CFO give an account of the past period regarding the Group's and each respective business area's results and financial position. The work on monthly closings and annual accounts is well-defined and reporting is in accordance with standardized reporting templates including comments regarding all material income and balance sheet items. There are CFOs and controllers with functional responsibility for accounting, reporting and analysis at both parent company

and subsidiaries. In this way the company's financial reports are checked several times, which reduces the risk of error.

At present neither the size of the company nor its risk exposure warrant a separate internal audit function. The Board assesses that with the procedures in place for follow-up and control there is currently no necessity for this.

Information and communication

CellaVision's procedures and systems for provision of information are aimed at supplying the market with relevant, reliable, correct and current information about the company's development and financial position. The Board has adopted an information policy that specifies what is to be communicated, by whom and in what way the information is to be published, to ensure that external information is correct and complete. Financial information is published regularly in the form of interim reports, annual report and press releases on price-sensitive news. The material is published in Swedish and English on the company's website.

Follow-up

Compliance and effectiveness of internal controls are followed up regularly. The company's financial situation and strategy regarding its financial position is dealt with at each Board meeting, when the Board receives detailed monthly reports regarding the financial position and development of operations. Each interim report is analyzed by the Audit Committee, discussed with the CFO and then approved by the Board before publication.

Activities in 2019

CellaVision works constantly to minimize risks by removing superfluous manual steps from the company's processes. In 2019 work continued on implementing a new group accounting system as part of this. In addition, efforts from the fourth quarter of 2019 were directed at integrating the acquired company RAL Diagnostics into the company's financial and economic processes to deliver a common result for the group.

Board of Directors & Auditors



Sören Mellstig

SÖREN MELLSTIG

Elected and Chairman of the Board since 2016.

Born: 1951

Other directorships: Chairman Ellevio AB (publ), Humana AB (publ), Impilo Holding AB, Delivery 1 Ltd and Remeo AB, ordinary member in Julins stiftelse. Former senior positions at AkzoNobel, CFO and vice president at Incentive, CFO, business area manager and CEO of Gambro 2000-2006.

Education: MBA.

Shares: 42 944



Christer Fåhræus

CHRISTER FÅHRAEUS

Founder and Member of the Board 1994 .

Born: 1965

Other directorships: President/CEO of EQL Pharma AB. Chairman Respiratorius AB, Umansense AB, Bionamic AB and Longboat Laboratories AB and ordinary member in Flatfrog Laboratories AB, Reccan AB, EQL Pharma AB, Scandidos AB, Serstech AB and Gasporox AB. Founder of Anoto Group AB, Precise Biometrics AB, Agellis Group AB and Flatfrog Laboratories AB among other things.

Education: B Sc Medicine, M Sc. Bioengineering, B Sc Mathematics, PhD Neurophysiology, PhD engineering (hc)

Shares: 2 316 000 (inc.comp).



Jurgen Riedl

JURGEN RIEDL

Member of the Board since 2018 .

Year of birth: 1977

Other directorships: Jürgen has a strong background in clinical laboratory work and is an internationally recognized expert in hematology. Jürgen has experience from several senior positions at Albert Schweitzer Hospital in Dordrecht, Beatrix Hospital in Gorinchem and Ikazia Hospital in Rotterdam in clinical chemistry and hematology.

Education: Post-doc & PhD

Shares: -



Anna Malm Bernsten

ANNA MALM BERNSTEN

Member of the Board since 2010.

Year of birth: 1961

Other directorships: CEO of Bernsten Konsult AB. Formerly President and CEO of Carmeda AB and senior positions in Pharmacia & Upjohn and GE Healthcare Life Sciences. Member of the Board Pågengruppen AB and BioLamina AB.

Education: M Sc. Chemical.

Shares: -



Stefan Wolf

STEFAN WOLF

Member of the since Board 2018.

Born: 1964

Other directorships: Division President of Immun Diagnostic Division at Thermo Fisher Scientific. Former experience include CEO for Hemostasis, Hematology and Speciality Diagnostics på Siemens Healthineers.

Education: Biological Laboratory Science

Shares: -



Niklas Prager

NIKLAS PRAGER

Member of the Board since 2014.

Born: 1970

Other directorships: Chariman of the Board in Qbtech AB, and member of the Board Adero AB. Former positions include CEO/President Medivir AB, Envirotainer AB, Qbtech AB och Pfizer AB.

Education: MBA

Shares: 8 720



Åsa Hedin

ÅSA HEDIN

Member of the Board since 2015.

Born: 1962

Other directorships: Chairman of the Board Artificial Solutions AB and ordinary member Nolato AB, Industrifonden AB, Crad AB, Tobii AB and Biotage AB. Former senior positions at Elekta AB, Siemens Healthcare and Gambro.

Education: MSc Biophysics

Shares: -

AUDITOR**MARIA EKELUND**

Authorised Public Accountant,

Deloitte AB.

Auditor of CellaVision since 2013

Management



Zlatko Rihter

ZLATKO RIHTER

President and CEO.
Employed in 2015

Year of birth: 1970

Other directorships: Member of the Board of ETAC AB and Malmö FF.

Previous experience: More than 20 years of experience from med. tech industry, holding leading positions at Gambro and ArjoHuntleigh. His most recent position was as Executive Vice President at Origio A/S.

Education: M.Sc. Mechanical Engineering, Economics.

Shares: 70,000



Magnus Blixt

MAGNUS BLIXT

CFO.

Employed in 2013

Year of birth: 1966.

Previous experience: Extensive experience of developing small and medium sized companies focusing on business performance and process improvements, within the SKF Group and Rotaform AB among others. He most recently held the position as Business Demand Manager at SKF AB.

Education: M. Sc. Finance

Shares: 8,000



Jeppe Brandstrup

JEPPE BRANDSTRUP

VP Business Development.

Employed in 2016

Year of birth: 1984

Previous experience: Many years of experience in business development and acquisitions in the life sciences industry. Most recently as Senior Acquisition Manager at Novozymes in Copenhagen.

Education: M. Sc Finance.

Shares: 2,500



Magnus Johnsson

MAGNUS JOHNSSON

VP Quality.

Employed in 2000-2008, 2016

Year of birth: 1975

Previous experience: More than 15 years of experience in med. tech industry from companies such as ArjoHuntleigh and Xellia Pharmaceuticals. Most recent position was at Xellia Pharmaceuticals.

Utbildning: M.Sc. Chemistry, B.Sc. Information Systems.

Shares: –



Magnus Lindeberg

MAGNUS LINDEBERG

VP Supply & Sourcing.

Employed in 2016

Year of birth: 1975

Previous experience: More than 20 years of experience in the medical device industry in various senior positions in the supply chain and production included Gambro. Comes from a position as Manager Materials Supply Baxter (formerly Gambro AB).

Education: M. Sc. Mechanical.

Shares: –



Mattias Lundin

MATTIAS LUNDIN

VP Global Sales.

Employed in 2015

Year of birth: 1968

Previous experience: Many years of experience from the medtech industry, holding leading positions in sales and marketing. Most recent position as VP Commercial for international and mature markets at ArjoHuntleigh, a company within Getinge group.

Education: Diploma in Business Administration & Marketing Management.

Shares: 900



Adam Morell

ADAM MORELL

VP Innovation & Engineering.

Employed in 2001-2003, 2006

Year of birth: 1976

Previous experience: Many years of experience as R&D Manager at CellaVision. Extensive expertise in the field of digital imaging and has been a co-inventor on several patents.

Education: Lic. of Engineering Mathematics, M.Sc. Engineering Physics,

Shares: –



Maria Morin

MARIA MORIN

VP HR & Corporate Communications.

Employed in 2009

Year of birth: 1974

Other directorships: Member of the Board Phase Holographic Imaging AB and ProstaLund AB

Previous experience: Extensive experience from various positions and companies within the field of human resources, most recent position was at Gambro.

Education: B.Sc Economics and Business Administration and B.Sc. Human Resources

CellaVision shares: –



Julien Veyssy

JULIEN VEYSSY

Managing Director RAL Diagnostics.

Employed: 2019 (2018 RAL Diagnostics)

Born: 1983

Previous experience: More than 13 years of experience in the IVD-industry and specifically in the hematology market. Most recent position Marketing manager at Sysmex, EMEA.

Shares: –



Peter Wilson

PETER WILSON

VP Global Marketing.

Employed in 2000

Born: 1967

Previous experience: Many years experience of global launching of new technologies and new products. Former positions include Foss, among others. Peter Wilson was head of CellaVisions subsidiary in North America in the years 2012-2014.

Education: M. Sc. Chemistry

Shares: 3 000